CG
PVLA

Cutler Group’s Palvella Therapeutics PVLA Stock Holding History

Cutler Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-60
Closed -$2K – 6266
2021
Q3 		$2K Sell
60
-365
-86% -$127K ﹤0.01% 5136
2021
Q2 		$6K Buy
+425
New +$93.2K ﹤0.01% 4359
2019
Q4 		– Sell
-68
Closed -$1K – 4742
2019
Q3 		$1K Buy
+68
New +$26.3K ﹤0.01% 3883
2018
Q3 		– Sell
-26
Closed -$1K – 4817
2018
Q2 		$1K Sell
26
-73
-74% -$34.7K ﹤0.01% 3998
2018
Q1 		$1K Buy
+99
New +$61.3K ﹤0.01% 4211

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Cutler Group's PVLA Position: Q1 2024 in Review

Cutler Group held its Palvella Therapeutics (PVLA) position steady in Q1 2024 at 56 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3858.

Cutler Group first reported a position in PVLA in Q3 2017 and has held it in 27 quarters since. The position peaked at $49K in Q2 2021. 41 funds tracked by Wall St. Rank hold PVLA as of Q1 2024.

  • Cutler Group held 56 shares of Palvella Therapeutics worth $0 as of Q1 2024.
  • Cutler Group left its Palvella Therapeutics share count unchanged in Q1 2024.
  • Palvella Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #3858 holding.
  • Cutler Group first reported a position in Palvella Therapeutics in Q3 2017 and has held it in 27 quarters since.
  • Cutler Group's Palvella Therapeutics position peaked at $49K in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.